Who We Are

MatriSys is the most clinically advanced skin microbiome company.

MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion worldwide dermatology and skin care market.

Founded in 2015, the company is developing rational microbiome therapies based on Dr. Richard L. Gallo’s basic and clinical research for the top 5 dermatology and skin care conditions – Acne, Atopic Dermatitis (AD), Rosacea, Psoriasis, and Skin Infections, which have a huge impact on patients’ quality of life. More than 230 million patients suffer from these 5 skin diseases.

Good Bacteria Help Prevent Skin Diseases by Fighting Bad Bacteria

MatriSys Bio’s scientific approach is to rebalance the natural skin microbiome by application of microbial therapies -“Good Bugs” that selectively target skin pathogens -“Bad Bugs”. Our lead microbiome Phase I/II clinical program addresses the Atopic Dermatitis (“AD”) market with 15 M US patients (132 M worldwide), is NIH funded, and IP protected with an exclusive license from UCSD. Our “Good Bug”, S. hominis, is highly potent against the “Bad Bug”, Staph. aureus, which has long been associated with AD. S. hominis does not affect other “Good Bugs” leading to the natural rebalance of the skin microbiome.

MatriSys Bioscience’s Solution is to Re-Balance Skin Health by Integrating the Skin Microbiome and the Innate Immune System

Our Intellectual Property offers multiple routes for commercialization: Rx Dermatology, Skin Care, and Cosmetic. Licensing discussions are currently underway for our first asset, S. hominis.

Pharma Applications

MatriSys Bio’s lead project MSB-01 is a novel, highly selective topical antimicrobial “Live Biotherapeutic Product” that replaces the bacteria  deficient on the skin of Atopic Dermatitis patients that are needed for host defense.

Learn More

Cosmetic and Skin Care Applications

To add value to the company in the cosmetic and skin care market, MatriSys Bio is developing novel cosmetic ingredients from the fermentation of its IP protected bacterial strains.

Learn More

Selected Publications

Professor Richard L. Gallo

UCSD Dermatology Professor Richard L. Gallo MD, PhD is a world leader in the use of microbes as novel medicines. He is a co-founder and head of MatriSys Bio’s Scientific Advisory Board. His work has focused on host defense and mutualistic interactions with microbes on the skin, with a particular interest in antimicrobial peptides and the basic functions of the skin microbiome.

View Full Bio